Document is current

Article History

Received: 11 January 2024

Accepted: 8 February 2024

First Online: 6 March 2024

Declarations

:

: Bhumika Aggarwal is an employee of GSK and holds shares in GSK. Paul Jones is an employee of GSK and holds shares in GSK. Alejandro Casas has received payment for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from GSK (Colombia, Chile, and Global), AstraZeneca (Colombia and LATAM), and Boehringer Ingelheim (Colombia and Ecuador); has received support for attending a Colombian National Congress and scientific meetings from GSK Colombia; and has received payment for participation on a Data Safety Monitoring Board or Advisory Board from GSK Colombia. Mauro Gomes has not received payments for the present manuscript; has received payment for class presentation from Boehringer-Ingelheim, Chiesi and GSK; and has received support for registration for the European Congress ERS 2023 from Chiesi. Siwasak Juthong has no conflicts of interest to disclose. Diego Litewka has received payments from GSK for conferences and advisory boards. Bernice Ong-Dela Cruz has received honoraria and advisory board fees from GSK, AstraZeneca, Boehringer Ingelheim, Orient Euro Pharma (OEP) and Pfizer; and receives honoraria from United American Pharmaceuticals (UAP). Alejandra Ramirez-Venegas has received honoraria for speaking engagements from GSK and AstraZeneca. Abdullah Sayiner has received honoraria for serving on advisory boards and for speaking at meetings sponsored by GSK, Chiesi and Abdi Ibrahim. James van Hasselt is an employee of GSK and holds shares in GSK. Chris Compton is an employee of GSK and holds shares in GSK. Lee Tombs is a contractor for Veramed and a director for Precise Approach Ltd, London; he was contracted by GSK to conduct the statistical analysis for this study but received no payment for manuscript development. Stephen Weng is an employee of GSK and holds shares in GSK. Gur Levy is an employee of GSK and holds shares in GSK.

: The present article is based on existing data from the phase 3 IMPACT trial and does not contain any new interventional studies with human participants or animal subjects performed by any of the authors. The IMPACT study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and received approval from local institutional review boards or independent ethics committees.